What is the impact of ARB on all-cause mortality in CKD class 3b-4?
Based on Table 62, the quality of evidence for the impact of ARB on all-cause mortality in CKD class 3b-4 is very low due to risk of bias, imprecision (from 32 fewer to 40 more). The number of participants in the study was 2917, and the follow-up was determined by the study. The anticipated absolute effects risk with placebo was not estimable, and the risk difference with ARB (95% CI) was from 32 fewer to 40 more.